Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KYMR
KYMR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KYMR News
Analysis of XBI ETF's 52-Week Price Fluctuations
6d ago
NASDAQ.COM
Kymera Completes Enrollment in Phase 2b Trial Ahead of Schedule
Jun 27 2026
NASDAQ.COM
Kymera Therapeutics Completes Enrollment Early in Key Clinical Trial
Jun 26 2026
Fool
Bio-Techne Soars Over 20% on Merck Acquisition News
Jun 26 2026
NASDAQ.COM
Kymera Accelerates Clinical Trial Timeline for KT-621
Jun 26 2026
stocktwits
Biotech Stocks Surge Amid Positive Trials and Earnings
Jun 25 2026
CNBC
Kymera Accelerates KT-621 Trial Data Timeline
Jun 25 2026
seekingalpha
Kymera Therapeutics Completes BROADEN2 Trial Enrollment Ahead of Schedule
Jun 25 2026
Newsfilter
Kymera Therapeutics Appoints New Chairman of the Board
Jun 25 2026
NASDAQ.COM
Kymera Therapeutics Appoints New Chairman of the Board
Jun 24 2026
Yahoo Finance
Kymera Therapeutics Presents KT-621 Phase 1 Study Results at JDA
Jun 12 2026
Newsfilter
Novartis Expands Deal with Orionis for Molecular Glue Drugs
Jun 11 2026
seekingalpha
Kymera Therapeutics Secures $20 Million Milestone Payment from Sanofi
Jun 09 2026
Yahoo Finance
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
May 17 2026
Yahoo Finance
Purcell & Lefkowitz Investigates Kymera Therapeutics for Fiduciary Breaches
May 12 2026
PRnewswire
Key Wall Street Rating Changes Overview
May 06 2026
CNBC
Show More News
